Home Busca Avançada Normas de Publicação Assinaturas Fale Conosco
Contact Us


Moreira Jr Editora
Proibida a reprodução sem autorização expressa

sêlo de qualidade
Like page on Facebook


Peripheral neuropathy is among the most commonly seen complications in patients undergoing multiple myeloma therapy. Bortezomib, a proteossome inhibitor, may cause neurotoxic effects, mainly sensorial neuropathy. These potentially debilitating adverse effects are frequently dose limiting, and they may interfere with optimal therapy and substantially affect patient quality of life as well as outcome. These effects are generally reversible with dose reduction or treatment discontinuation. However we still don’t know when will be the best time to intervein. Another promissing approach is a once a week dosing of bortezomib that has demonstrated lower rates of peripheral neuropathy without compromising efficacy. The weekly doses proved to maintain the quality and response, with a significant reduction in adverse events. This article reviews bortezomib induced peripheral neuropathy and discusses set goals to prevent, identify, and treat neurotoxic effects related to this drug. To improve control of the peripheral neuropathy, the authors propose a multidisciplinary work that would include a doctor-nurse partnership with the identification of the adverse event, early intervention and a consequential change in the history of the neuropathy.

Moreira JR Editora